Loading
Give a small number of scientists a decade of guaranteed funding to work on a single hard problem such as dormant cancer cells, with no pressure to publish quickly.
The typical grant cycle of three to five years pushes researchers towards problems that yield papers on that timescale. Metastasis, dormancy, cachexia, tumour immunology in cold tumours and undruggable drivers need longer bets. A funder would award 10-year, person-based grants to mid-career investigators who commit to one such problem, assessed at year five on process (data shared, tools built, negative results published) rather than publication counts. Precedents are the Howard Hughes Medical Institute investigator model and the Wellcome Trust's long-term fellowships.
Shares Klaus Pantel, Dormant cells and minimal residual disease.
Shares Klaus Pantel, Metastasis is understood least and studied last.
Shares Metastasis is understood least and studied last, Funding follows fashion, not burden.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease.
Shares Charles Swanton, Metastasis is understood least and studied last.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease.